marked.bio

Company

Jiangxi Kvvit Pharmaceutical

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

    Not yet recruiting Phase 2/3 Jiangxi Kvvit Pharmaceutical Starts 2027Primary completion 2029-02 NCT07656376

    DN022150+AG( Stage I ）DN022150+AG（Stage II）

    Subjects with confirmed KRAS G12D who have not received prior systemic antineoplastic therapy for advanced or metastatic pa…

    KRAS G12DPancreatic Cancer, Pancreatic Carcinoma

  2. Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

    Not yet recruiting Phase 3 Jiangxi Kvvit Pharmaceutical Started 2026Primary completion 2028-07 NCT07689539

    DN022150Chemotherapy

    Subjects with confirmed KRAS G12D who have received prior systemic therapy for advanced or metastatic pancreatic cancer

    KRAS G12DPancreatic Cancer